Fred Hutchinson Cancer Center

University of Washington

Vanderbilt University

John R Chevillet

Valeri I Vasioukhin

Tatiana Khokhlova

George R Schade

Joo Ha Hwang

Robert J Matusik

Olga Klezovitch

Muneesh Tewari

The present disclosure is directed to relates to systems and methods for evaluating tissue using high intensity focused ultrasound (HIFU) energy. In one embodiment, for example, a system for treating a patient comprises an ultrasound source configured to deliver HIFU energy to a target tissue mass of the patient and a function generator operably coupled to the ultrasound source for initiating a pulsing protocol for delivering the HIFU energy. The system further comprises a controller configured to perform operations comprising applying HIFU energy to induce cavitation in the target tissue mass and cause a biomarker to be released, comparing a baseline concentration of the biomarker from a first fluid sample to a concentration of the biomarker in a second fluid sample within 2 hours after applying HIFU, and repeating the applying and comparing until the concentration of the biomarker in the fluid sample falls below a threshold value.

Systems and methods for evaluating tissue of a subject

Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors.

Hepsin inhibitors

Transgenic, non-human animal model of cancer, methods of making such animals and methods of using such animals to screen test compounds are provided.

Mouse models of prostate cancer development and metastasis through expression of a hepsin transgene

Growing community of inventors

Seattle, WA, United States of America

John R Chevillet